Drug Profile

Research programme: proteolysis targeting chimeric molecules - Arvinas

Latest Information Update: 21 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

31 Dec 2024 Proteolysis targeting chimeric molecules still in research for Cancer, Cardiovascular disorders and Female genital diseases in USA and Germany (Arvinas SEC File- December 2024)
12 Aug 2024 Arvinas terminates its agreement with Bayer to develop proteolysis targeting chimeric molecules (Arvinas SEC File- December 2024)
28 Jul 2023 No recent reports of development identified for research development in Cancer in Germany

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com